Show simple item record

dc.contributor.authorSaketkoo, LA
dc.contributor.authorEscorpizo, R
dc.contributor.authorVarga, J
dc.contributor.authorKeen, KJ
dc.contributor.authorFligelstone, K
dc.contributor.authorBirring, SS
dc.contributor.authorAlexanderson, H
dc.contributor.authorPettersson, H
dc.contributor.authorChaudhry, HA
dc.contributor.authorPoole, JL
dc.contributor.authorRegardt, M
dc.contributor.authorLeSage, D
dc.contributor.authorSarver, C
dc.contributor.authorLanario, Joseph
dc.contributor.authorRenzoni, E
dc.contributor.authorScholand, MB
dc.contributor.authorLammi, MR
dc.contributor.authorKowal-Bielecka, O
dc.contributor.authorDistler, O
dc.contributor.authorFrech, T
dc.contributor.authorShapiro, L
dc.contributor.authorVarju, C
dc.contributor.authorVolkmann, ER
dc.contributor.authorBernstein, EJ
dc.contributor.authorDrent, M
dc.contributor.authorObi, ON
dc.contributor.authorPatterson, KC
dc.contributor.authorRussell, A-M
dc.date.accessioned2023-01-09T14:00:36Z
dc.date.issued2022-10-14
dc.identifier.issn1663-9812
dc.identifier.issn1663-9812
dc.identifier.urihttp://hdl.handle.net/10026.1/20150
dc.description.abstract

Background: The World Health Organization (WHO) introduced the International Classification of Functioning, Disability, and Health (ICF) as a scientific method of disability data collection comprised of >1,200 categories describing the spectrum of impairment types (functional, symptoms-based and anatomical) under the bio-psycho-social model with consideration of environmental and personal factors (pf). ICF Core Sets and ICF Checklists are streamlined disease-specific resources for clinical use, service provision, and for use in health economics and health policy. ICF can disclose strengths and weaknesses across multiple patient-reported outcome measures (PROMs) and help consolidate best-fitting question-items from multiple PROMs. Interstitial lung diseases (ILDs), are generally progressive, with restrictive physiology sometimes occurring in the context of multi-organ autoimmunity/inflammatory conditions such as connective tissue diseases (CTDs). In spite of significant associated morbidity and potential disability, ILD has yet to be linked to the ICF.Methods: Each instrument and their question-items within the consensus-recommended core sets for clinical trials in ILD were deconstructed to single concept units, and then linked per updated ICF linkage rules. Inter-linker agreement was established. Three additional subsequently validated measures were also included.Results: One-hundred-eleven ICF categories were identified for ten PROMs and three traditional objective measures that were amenable to ICF linkage. The proportion of agreement ranged from 0.79 (95% CI: 0.62, 0.91) to 0.93 (0.76, 0.99) with the overall proportion of inter-linker agreement being very high 0.86 (0.82, 0.89) for the initial instruments, with 94–100% for the three additional PROMs. Thirty-four new ‘Personal Factors’ emerged to capture disease-specific qualities not elsewhere described in ICF, e.g. ‘pf_embarrassed by cough’ or ‘pf_panic/afraid when can’t get a breath’.Conclusion: This first known effort in ICF linkage of ILD has provided important revelations on the current utility of the ICF in lung disease. Results have indicated areas for meaningful assessment of ICF descriptors for lung impairment. The mapping across PROMs provides insight into possibilities of developing more streamline and precise instrumentation. Finally, familiarity with the ICF in ILD may enable clinicians to experience a smoother transition with the imminent harmonization of ICD and ICF, ICD-11.

dc.format.extent979788-
dc.format.mediumElectronic-eCollection
dc.languageeng
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCTD-ILD
dc.subjectICD-11
dc.subjectconnective tissue
dc.subjectcough
dc.subjectfibrosis
dc.subjectpatient-reported outcomes
dc.titleWorld Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36313333
plymouth.volume13
plymouth.publication-statusPublished online
plymouth.journalFrontiers in Pharmacology
dc.identifier.doi10.3389/fphar.2022.979788
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/FoH - Community and Primary Care
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeSwitzerland
dcterms.dateAccepted2022-07-13
dc.rights.embargodate2023-1-12
dc.identifier.eissn1663-9812
rioxxterms.versionofrecord10.3389/fphar.2022.979788
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.licenseref.startdate2022
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV